InnoCare Pharma (FRA:33C) Other Operating Expense : €15.80 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Other Operating Expense?

InnoCare Pharma's Other Operating Expense for the three months ended in Dec. 2023 was €32.08 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €15.80 Mil.

InnoCare Pharma's quarterly Other Operating Expense declined from Jun. 2023 (€0.00 Mil) to Sep. 2023 (€-15.48 Mil) but then increased from Sep. 2023 (€-15.48 Mil) to Dec. 2023 (€32.08 Mil).

InnoCare Pharma's annual Other Operating Expense increased from Dec. 2021 (€10.94 Mil) to Dec. 2022 (€35.81 Mil) but then declined from Dec. 2022 (€35.81 Mil) to Dec. 2023 (€32.94 Mil).

InnoCare Pharma Other Operating Expense Historical Data

The historical data trend for InnoCare Pharma's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Other Operating Expense Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

0.34

-2.52

10.94

35.81

32.94

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Other Operating Expense	Get a 7-Day Free Trial												35.33	-	-15.48	32.08	-0.80

InnoCare Pharma Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €15.80 Mil.

InnoCare Pharma Other Operating Expense Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (FRA:33C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

09969:Hong Kong 33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines